ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO1036

Impact of Diabetic Nephropathy on Morbidity and Mortality in a Large Cohort of Hemodialysis Patients in Saudi Arabia

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Abderrahim, Ezzedine, Davita Saudi Arabia, Riyadh, Saudi Arabia
  • Sabri, Ayman, Davita Care-KSA, Riyadh, Saudi Arabia
  • Ahmed, Mahmoud Ahmed mohamed, Davita Care-KSA, Riyadh, Saudi Arabia
  • Alobaili, Saad S., Davita Care-KSA, Riyadh, Saudi Arabia
  • Dridi, Afef, Davita Care-KSA, Riyadh, Saudi Arabia
  • Jubran, Ibrahim Abduh, Davita Care-KSA, Riyadh, Saudi Arabia
  • Al-Badr, Wisam H.A., Davita Care-KSA, Riyadh, Saudi Arabia
Background

The aim of this study was to evaluate the impact of diabetes as a cause of ESRD on morbidity and mortality in a large cohort of Saudi hemodialysis patients.

Methods

All patients referred to Davita-Saudi Arabia clinics to continue ESRD treatment with hemodialysis from October 2014 to December 2018 were included in this analysis. The study population was divided in Group 1, corresponding to patients referred with the diagnosis of diabetes as a cause of ESRD and, Group 2, in whom ESRD was attributed to other causes with or without diabetes as a comorbidity. Mortality and hospitalization rates were calculated by dividing the number of events by the cumulative period of follow-up. Logistic regression was used to identify parameters that were independently associated with mortality and hospitalization.

Results

The cohort included 3508 patients (54% men). Patients with diabetic nephropathy represented 40.3% of included patients (G1), their mean age was of 58.1 ± 14.5 years vs. 48.7 ± 17.4 in Group 2 (p<0.0001). There was a slight male predominance in both groups with a sex ratio of 1.20 in G1 vs. 1.16 in G2 (NS). The proportion of patients who were hospitalized was of 31.7% in G1 vs. 22.3% in G2 (p<0.0001), corresponding to a rate of 38.8 per 100 patient-years (CI, 95%: [36.15-41.46]) in G1 vs. 21.8 per 100 patient-years (CI, 95%: [20.20-23.31]) in G2. Mean duration of hospital stay was of 4.8 days per patient in G1 (CI, 95%: [4.8-4.9]) vs 2.5 days in G2 (CI, 95%: [1.4-2.5]). The mortality rate was of 10.5 per 100 patient-years in G1 (CI, 95%: [9.10-11.86]) vs. 5.1 in G2 (CI, 95%: [4.33-5.83]). After adjustment for age, gender, type of vascular access and, time on HD, hospitalization, and mortality risks were of 1.61 (CI, 95%: [1.33-2.11]) and 1.47 (CI, 95%: [1.24-1.73]) in G1 compared to G2.

Conclusion

Saudi patients hemodialyzed for ESRD related to diabetic nephropathy, are with a higher risk for the number of hospitalization, hospital length stay and, mortality in comparison to those hemodialyzed for other causes.